These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15667805)

  • 1. Immunochemotherapy of metastatic renal cell carcinoma: report of 28 cases.
    Wang HJ; Chen HX; Li HZ
    Chin Med J (Engl); 2005 Jan; 118(2):172-3. PubMed ID: 15667805
    [No Abstract]   [Full Text] [Related]  

  • 2. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
    Tai CJ
    Acta Oncol; 2009; 48(6):931-2. PubMed ID: 19925379
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
    Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
    Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current status of chemotherapy for renal cell carcinoma].
    Kato T; Sato K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):23-8. PubMed ID: 8291912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
    Herrmann E; Brinkmann OA; Bode ME; Bierer S; Köpke T; Bögemann M; Hertle L; Wülfing C
    Eur Urol; 2007 Jun; 51(6):1625-31; discussion 1631-2. PubMed ID: 17113215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
    Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
    J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European studies of interleukin-2 in metastatic renal cell carcinoma.
    Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
    [No Abstract]   [Full Text] [Related]  

  • 13. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of UFT for the treatment of renal cell carcinoma.
    Masuda F; Mori Y; Nakada J
    Prog Clin Biol Res; 1989; 303():707-9. PubMed ID: 2506559
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical study on the effects of chemotherapy as treatment of renal cell carcinoma].
    Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):43-9. PubMed ID: 3379331
    [No Abstract]   [Full Text] [Related]  

  • 18. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.
    Droz JP; Theodore C; Ghosn M; Lupera H; Piot G; De Forges A; Klink M; Rouesse J; Amiel JL
    Semin Surg Oncol; 1988; 4(2):97-9. PubMed ID: 3393780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of UFT in far-advanced renal cell carcinoma].
    Matsuyama H; Yamamoto N; Sakatoku J; Hara Y; Sacho T; Yasui H; Ichikawa T; Koshido Y; Hayasida S; Nagata K
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):527-30. PubMed ID: 3126711
    [No Abstract]   [Full Text] [Related]  

  • 20. Dexamethasone and interleukin-2 combination therapy for advanced renal cell carcinoma in a patient with paraneoplastic inflammatory syndrome.
    Shinojima T; Oya M; Kohno H; Marumo K; Murai M
    Int J Urol; 2004 Jul; 11(7):553-6. PubMed ID: 15242368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.